(PINK) Simplify Exchange Traded - Ratings and Ratios
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US82889N7729 • Health
PINK: Medicines, Medical, Healthcare, Biotech, Pharmaceuticals, Diagnostics
The Simplify Health Care ETF (NYSE ARCA:PINK) is a targeted investment fund designed to provide exposure to U.S. health care companies. Under normal market conditions, the fund allocates at least 80% of its assets (including borrowings for investment purposes) to securities within the health care sector, as defined by the Global Industry Classification Standard (GICS). This includes companies involved in pharmaceuticals, biotechnology, medical devices, and health care services. The fund typically holds between 50 to 100 positions, focusing on firms that are either developing innovative medical treatments or implementing cost-effective solutions to enhance health care delivery.
The funds investment strategy emphasizes companies that are advancing medical innovation, such as those working on new drug therapies or diagnostic tools. Additionally, it seeks out businesses that improve operational efficiency or reduce costs within the health care system, such as telemedicine providers or companies specializing in health care IT. This dual focus aims to capture growth opportunities across the entire health care value chain.
Over the next three months, the Simplify Health Care ETF (PINK) is expected to trade within a narrow range, influenced by its current technical and fundamental profile. Based on the SMA 20, SMA 50, and SMA 200, the fund is currently trading slightly below its short-term and long-term moving averages, suggesting a period of consolidation. The ATR of 0.44 indicates moderate volatility, with potential price fluctuations of approximately 1.32% to 1.76% over the next quarter.
The funds AUM of $150.59M reflects a stable asset base, which may support liquidity and reduce the impact of market volatility. Average daily trading volume of 59,949 shares suggests moderate liquidity, which could influence price movements in response to sector-specific news or broader market trends. Overall, the ETF is likely to remain range-bound, with upside potential tied to innovation in the health care sector and downside risk linked to regulatory or market uncertainties.
Additional Sources for PINK ETF
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PINK ETF Overview
| Market Cap in USD | 151m |
| Category | Health |
| TER | 0.50% |
| IPO / Inception | 2021-10-07 |
PINK ETF Ratings
| Growth 5y | 28.2% |
| Fundamental | - |
| Dividend | 37.8% |
| Rel. Strength Industry | -10.7 |
| Analysts | - |
| Fair Price Momentum | 26.81 USD |
| Fair Price DCF | - |
PINK Dividends
| Dividend Yield 12m | 0.32% |
| Yield on Cost 5y | 0.38% |
| Annual Growth 5y | 67.30% |
| Payout Consistency | 66.9% |
PINK Growth Ratios
| Growth Correlation 3m | -30.1% |
| Growth Correlation 12m | 14.8% |
| Growth Correlation 5y | 70% |
| CAGR 5y | 4.93% |
| CAGR/Max DD 5y | 0.27 |
| Sharpe Ratio 12m | -0.56 |
| Alpha | -10.11 |
| Beta | 0.64 |
| Volatility | 16.68% |
| Current Volume | 95.6k |
| Average Volume 20d | 68.5k |
As of March 14, 2025, the stock is trading at USD 28.87 with a total of 95,641 shares traded.
Over the past week, the price has changed by -3.99%, over one month by -3.70%, over three months by -4.83% and over the past year by -3.32%.
Neither. Based on ValueRay Analyses, Simplify Exchange Traded is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 28.16 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PINK as of March 2025 is 26.81. This means that PINK is currently overvalued and has a potential downside of -7.14%.
Simplify Exchange Traded has no consensus analysts rating.
According to ValueRays Forecast Model, PINK Simplify Exchange Traded will be worth about 29.5 in March 2026. The stock is currently trading at 28.87. This means that the stock has a potential upside of +2.15%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 29.5 | 2.1% |